Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2C adrenoreceptor antagonists

Details for Australian Patent Application No. 2005318188 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Langlois, Xavier Jean Michel; PastorFernandez, Joaquin; Alcazar-Vaca, Manuel Jesus; Oyarzabal-Santamarina, Julen; Andres-Gil, Jose Ignacio; Drinkenburg, Wilhelmus Helena Ignatius Maria; Vega-Ramiro, Juan Antonio

Agent Shelston IP

Pub. Number AU-A-2005318188

PCT Pub. Number WO2006/067139

Priority 05104873.4 03.06.05 EP; 04106817.2 21.12.04 EP

Filing date 20 December 2005

Wipo publication date 29 June 2006

International Classifications

C07D 249/12 (2006.01) Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/4166 (2006.01)

A61K 31/4196 (2006.01) - 1,2,4-Triazoles

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 233/70 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 257/04 (2006.01) Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/10 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/10 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

2 August 2007 PCT application entered the National Phase

  PCT publication WO2006/067139 Priority application(s): WO2006/067139

14 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005318190-Cladribine regimen for treating multiple sclerosis

2005318187-Injectable veterinary composition